Cost-of-illness in systemic sclerosis: A retrospective study of an italian cohort of 106 patients;Analisi dei costi nella sclerosi sistemica. Studio retrospettivo in una casistica di 106 pazienti

Reumatismo

Volumn 55, Issue 4, 2003, Pages 245-255

  Belotti Masserini, A ^a   Zeni, Selvana ^a,b   Cossutta, R ^a   Soldi, A ^a   Fantini, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Cost of illness; Health care economics and policy; Predictors of costs; Systemic sclerosis

Indexed keywords

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BUDGET; CALCULATION; COHORT ANALYSIS; DIAGNOSIS RELATED GROUP; DISEASE DURATION; ECONOMIC ASPECT; EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PAIN; PATIENT REFERRAL; PREDICTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

AGED; FEMALE; HEALTH CARE COSTS; HUMANS; ITALY; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 1642557247     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Montanelli R, Gerzelli S. Introduzione agli studi di costo sociale delle malattie. Reumatismo 2001; 53: 68-74.
2. Sutcliffe N, Clarke E, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology 2001; 40: 37-47.
3. Lubeck DP. Healt care economics and policy. Curr Opin Rheumatol 1991; 3: 286-90.
4. Gold ML, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996.
5. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current pratices and procedures. Milbank Mem Fund Q 1982; 60: 429-62.
6. Luce BR, Elixhauser A. Estimating cost in the economic evaluation of medical technologies. Int J Technol Assess Healt Care 1990; 6: 57-75.
7. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Universirty Press, 1987.
8. Solan FA. Valuing Healt Care: Cost, Benefits and Effectiveness of Pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995.
9. Koopmanschap MA, Van Ineveld BM. Towards a new approach for estimating indirect cost of disease. Soc Sci Med 1992; 34: 1005-10.
10. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect cost of disease. J Health Econ 1995; 14: 171-89.
11. Statistics Canada. Households'unpaid work: Measurement and valuation 3rd ed. In: Canadian Economic Observer. Ottawa: Minister of Industry, 1995: 13-603.
12. Ashenfelter OC, Layard R. Home production: a survey. In: Handbook of labor economics. Amsterdam: Elsevier Sience, 1986: 273-304.
13. Statistics Canada. Earning of men and women, 1995. In: Canadian Economic Observer. Ottawa: Minister of Industry, 1997: 13-217.
14. Statistics Canada. The value of hausehold work in Canada, 1986. In: Canadian Economic Observer. Ottawa: Minister of Industry, 1992: 11-110.
15. Clarke AE, Pendrot J, St Pierre YS, Petri MA, Manzi S, IsenbergDA et al. Understimating the value of women: assessing the indirect cost of women with systemic lupus erythematosus. J Rheumatol 2000; 27: 2897-904.
16. Gordon C, Clarke AE. Quality of life and economic evaluation in SLE clinical trials. Lupus 1999; 8: 645-54.
17. Talamo J, Frater A, Gallivan S, Young A. Use of the Short Form 36 (SF-36) for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997; 36: 463-69.
18. Apolone G, Mosconi P, Ware JE Jr. Questionario sullo stato di salute SF-36; manuale d'uso e guida all'interpretazione dei risultati. Milano: Guerini e Associati, 1997.
19. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine Physical Disability in systemic sclerosis. Arthritis Care Res 1991; 4: 27-31.
20. Clarke AE, Esdaile JM, Bloch DA. Canadian study of the total medical cost for patients with systemic lupus erythematosus and the predictor cost. Arthritis Rheum 1993; 36: 1548-49.
21. Clarke AE, Petri MA, Manzi S. An international perspective on the well being and health care cost of patient with systemic lupus erythematosus. J Rheumatol 1999; 26: 1500-11.
22. St Perre YS, Penrod J, Petri M. Understimating the value of rheumatic disease: assessing the cost of women with lupus (SLE). Arthritis Rheum 1998; 41: 221.
23. Ruof J, Hulsemann JL, Stucki G. Evaluation of cost in rheumatic disease: a literature review. Curr Opin Rheumatol 1999; 11: 104-09.
24. Wilson L. Cost-of-illness of Scleroderma: the case for rare disease. Semin Arthritis Rheum 1997; 27: 73-84.
25. Steen VD, Medsger TA Jr. Epidemiology and natural history of systemic sclerosis. Arthritis Rheum 1995; 38: 351-60.
26. Maetzel A. Costs of illness and the burden of disease. J. Rheumatol 1997; 24: 3-5.
27. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic Sclerosis: demographic, clinical and serologic features and survival in 1.012 Italian patient. Medicine 2002; 81: 139-53.